A biotechnology company developing stem cell therapies to treat neurodegenerative diseases
Our proprietary technology converts mesenchymal stem cells into NurOwn®, a biological drug delivery system designed to support damaged neurons
NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.
BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
July 25, 2017BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
July 21, 2017Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS
July 18, 2017BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS
On July 17th, the Northeast ALS Consortium (NEALS) hosted a research webinar on the NurOwn® Clinical Development Program: Promising Phase 2 Results, Phase 3 Study Overview, and Hospital Exemption Program Update. They were joined by Robert Brown, MD, DPhil, University of Massachusetts, Merit Cudkowicz, MD, MSc, Massachusetts General Hospital, Anthony Windebank, MD, Mayo Clinic, Ralph Kern, MD, MHSc, BrainStorm Cell Therapeutics and Chaim Lebovits, BrainStorm Cell Therapeutics.